Kiniksa Pharmaceuticals (KNSA) to Release Quarterly Earnings on Wednesday

Kiniksa Pharmaceuticals (NASDAQ:KNSA) is expected to be issuing its quarterly earnings data before the market opens on Wednesday, February 26th. Analysts expect the company to announce earnings of ($0.06) per share for the quarter.

Kiniksa Pharmaceuticals Stock Down 1.0 %

KNSA stock opened at $19.55 on Wednesday. The firm has a market cap of $1.41 billion, a PE ratio of -139.63 and a beta of 0.32. The business has a 50 day moving average of $19.75 and a 200 day moving average of $22.76. Kiniksa Pharmaceuticals has a twelve month low of $16.56 and a twelve month high of $28.15.

Insiders Place Their Bets

In other Kiniksa Pharmaceuticals news, CFO Mark Ragosa sold 8,969 shares of the business’s stock in a transaction that occurred on Tuesday, December 3rd. The stock was sold at an average price of $21.45, for a total transaction of $192,385.05. Following the sale, the chief financial officer now directly owns 22,958 shares of the company’s stock, valued at $492,449.10. The trade was a 28.09 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, COO Eben Tessari sold 14,000 shares of the business’s stock in a transaction that occurred on Monday, February 10th. The stock was sold at an average price of $19.57, for a total value of $273,980.00. Following the sale, the chief operating officer now directly owns 81,975 shares in the company, valued at $1,604,250.75. The trade was a 14.59 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 38,092 shares of company stock valued at $745,589 over the last ninety days. 54.57% of the stock is owned by insiders.

Analyst Ratings Changes

A number of research firms have recently issued reports on KNSA. Evercore ISI raised their price target on Kiniksa Pharmaceuticals from $30.00 to $35.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 30th. JPMorgan Chase & Co. raised their price target on Kiniksa Pharmaceuticals from $39.00 to $40.00 and gave the company an “overweight” rating in a report on Tuesday, November 5th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $34.00 target price on shares of Kiniksa Pharmaceuticals in a report on Monday, January 13th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $36.60.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.